预约演示
更新于：2025-09-05
Vincristine Sulfate
硫酸长春新碱
更新于：2025-09-05
概要
基本信息
药物类型 小分子化药 |
别名 22-Oxovincaleukoblastin、22-Oxovincaleukoblastine、Leurocristine + [16] |
靶点 |
作用方式 抑制剂 |
作用机制 PSMA抑制剂(前列腺癌特异性膜抗原抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C46H58N4O14S |
InChIKeyAQTQHPDCURKLKT-PNYVAJAMSA-N |
CAS号2068-78-2 |
关联
1,109
项与 硫酸长春新碱 相关的临床试验NCT05521087
A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations
NCT07133997
A Phase 1/1b Study Evaluating Asparaginase Erwinia Chrysanthemi- Recombinant-Rywn (Recombinant Erwinia Asparaginase) and Venetoclax in Combination With Blinatumomab in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
NCT07072585
A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)
100 项与 硫酸长春新碱 相关的临床结果
登录后查看更多信息
100 项与 硫酸长春新碱 相关的转化医学
登录后查看更多信息
100 项与 硫酸长春新碱 相关的专利（医药）
登录后查看更多信息
14,604
项与 硫酸长春新碱 相关的文献（医药）2025-12-31Hematology
Dose adjusted EPOCH-R is superior to RCHOP in frontline treatment of mediastinal large B cell lymphoma
Article
作者: Shahin, Omar ; Abufara, Alaa ; Al-Rwashdeh, Mohammad ; Muqbel, Ro’a ; Halahleh, Khalid ; Al-rabi, Kamal ; Al-Ibraheem, Akram ; Abed, Nebras Abu ; Farfoura, Heba ; Abdel-Razeq, Hikmat ; Ma'koseh, Mohammad ; Yaseen, Abeer ; Rahman, Zaid Abdel
INTRODUCTION:
Primary Mediastinal Large B Cell Lymphoma (PMLBCL) is a rare but aggressive B-cell lymphoma. This study compares the outcomes and toxicities of DA-EPOCH-R (Dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin in combination with rituximab) and RCHOP-21 (rituximab, cyclophosphamide, doxorubicin, and vincristine, every 21 days) in the treatment of newly diagnosed PMLBCL.
METHODS:
We retrospectively reviewed the medical records of adults (>18 years) diagnosed with PMLBCL and treated at our center from 2010 to 2023. Baseline characteristics were compared using chi-square and Mann Whitney U-tests. Survival outcomes were analysed using Kaplan Meier and log-rank tests.
RESULTS:
Eighty-seven patients were included, with a median age of 30 years (range: 18-55), 48 patients (55.2%) received RCHOP-21, and 39 patients (44.8%) received DA-EPOCH-R. Radiotherapy was more frequent in the RCHOP-21 group (66.6% vs 15%, p < 0.001). DA-EPOCH-R achieved a higher complete metabolic response (CMR) (92% vs 69%, p = 0.007). After a median follow-up of 47.4 months, patients treated with DA-EPOCH-R had superior overall survival (OS) and progression free survival (PFS); 3-year OS rates were 94.4% vs 69.8% (p = 0.01) and the 3-year PFS rates were 86.7% vs 62.2% (p = 0.016), particularly in patients with aa-IPI >1. Post-chemotherapy delta SUV max <0.75, and <0.7 correlated with relapse and mortality, respectively. Grade III-IV anemia and non-hematological toxicities were more frequent in the DA-EPOCH-R, but no therapy-related deaths occurred.
CONCLUSIONS:
DA-EPOCH-R improves CMR, PFS, and OS compared to R-CHOP-21 with radiotherapy in PMLBCL, particularly in high-risk patients. Longer follow-up is needed to assess long-term toxicities.
2025-12-01Blood Research
Real-world data analysis of survival outcomes of patients with primary mediastinal large B-cell lymphoma treated with immunochemotherapy: the role of consolidative radiation therapy
Article
作者: Lee, Yong-Pyo ; Yoon, Sang Eun ; Oh, Dongryul ; Ko, Young Hyeh ; Kim, Won Seog ; Kim, Seok Jin ; Cho, Junhun
Abstract:
Purpose:
Primary mediastinal large B-cell lymphoma (PMBCL) is a rare subtype of diffuse large B-cell lymphoma. Radiation therapy (RT) has served as the primary treatment option for PMBCL; however, its role has been questioned with the advent of intensified immunochemotherapy. This study aimed to investigate the role of consolidative RT in the primary treatment of PMBCL.
Methods:
This single-center retrospective study analyzed the survival outcomes of 65 patients newly diagnosed with PMBCL. The patients were divided into three treatment groups: (1) EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab), (2) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), and (3) R-CHOP with consolidative RT.
Results:
The objective response and complete remission rates were 86.2% and 63.1%, respectively, with 3-year progression-free survival (PFS) and overall survival (OS) rates of 72% and 81%, respectively. All patients in the R-CHOP + RT group achieved an objective response with better PFS) than those who did not receive consolidative RT (p = 0.028), although there was no significant difference in OS (p = 0.102). Consolidative RT benefited patients with an initially bulky disease or insufficient end-of-treatment response. The predictive value of 18F-fluorodeoxyglucose positron-emission tomography-computed tomography (PET-CT) in assessing the treatment response in PMBCL was revalidated, showing that patients who achieved negative end-of-treatment PET-CT had significantly better survival outcomes than others.
Conclusions:
R-CHOP is a useful alternative regimen when intensified chemotherapy is not feasible. Consolidative RT should be considered in cases with an initially bulky disease and insufficient end-of-treatment response.
2025-12-01TISSUE & CELL
A combined therapeutic approach: Parthenolide and vincristine modulate autophagy in B-cell acute lymphoblastic leukemia
Article
作者: Zare, Farahnaz ; Zarei, Elmira ; Omidkhoda, Azadeh ; Tamaddon, Gholamhossein ; Dehbidi, Gholamreza Rafiei ; Nazari, Mansoureh ; Namdari, Sepide
BACKGROUND:
Parthenolide (PTL), derived from Tanacetum parthenium, is known for its anti-inflammatory and anti-cancer properties, primarily through NF-κB inhibition and modulation of reactive oxygen species. This study investigates PTL's potential as a complementary treatment for B-Cell Acute Lymphoblastic Leukemia, focusing on its effects on autophagy, apoptosis, and proliferation in the Nalm-6 cell line, alongside vincristine, with the aim of addressing challenges such as multi-drug resistance.
METHODS:
Nalm-6 cells were treated with increasing concentrations of PTL and VCR to determine their IC50 values, followed by combination treatments with sub-IC50 doses. Apoptosis was assessed using flow cytometry, while changes in autophagy-related gene expression (BECN1, ATG10, LC3, and P62) were measured via Real-time PCR, and LC3 protein levels were analyzed through Immunoblotting.
RESULTS:
The results revealed that both PTL and VCR inhibited Nalm-6 cell proliferation in a concentration and time-dependent manner, with a synergistic effect observed in combined treatments. This combination also increased apoptosis and significantly enhanced the expression of autophagy-related genes ATG10, LC3 and BECN1 while decreasing P62 expression. Additionally, VCR and PTL increased LC3B-II protein levels.
CONCLUSION:
Overall, the study indicates that combined treatment promotes autophagy and apoptosis, suggesting that PTL could be a beneficial adjunct to chemotherapy for treating B-ALL in the future.
100 项与 硫酸长春新碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 嗜铬细胞瘤 | 日本 | 2013-03-26 | |
| 广泛期小细胞肺癌 | 巴西 | 2006-11-20 | |
| 女性生殖器官肿瘤 | 巴西 | 2006-11-20 | |
| 蕈样真菌病 | 巴西 | 2006-11-20 | |
| 骨肉瘤 | 巴西 | 2006-11-20 | |
| 横纹肌肉瘤 | 巴西 | 2006-11-20 | |
| 宫颈癌 | 巴西 | 2006-11-20 | |
| 星形细胞瘤 | 日本 | 2005-02-14 | |
| 胶质瘤 | 日本 | 2005-02-14 | |
| 尤文肉瘤 | 中国 | 1982-01-01 | |
| 白血病 | 中国 | 1982-01-01 | |
| 白血病 | 中国 | 1982-01-01 | |
| 黑色素瘤 | 中国 | 1982-01-01 | |
| 神经母细胞瘤 | 中国 | 1982-01-01 | |
| 神经母细胞瘤 | 中国 | 1982-01-01 | |
| 小细胞肺癌 | 中国 | 1982-01-01 | |
| 肾母细胞瘤 | 中国 | 1982-01-01 | |
| 急性白血病 | 日本 | 1968-04-18 | |
| 慢性白血病 | 日本 | 1968-04-18 | |
| 急性淋巴细胞白血病 | 美国 | 1963-07-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴母细胞淋巴瘤 | 临床2期 | 美国 | 2025-01-23 | |
| 淋巴母细胞淋巴瘤 | 临床2期 | 美国 | 2025-01-23 | |
| 前体B细胞急性淋巴细胞白血病 | 临床2期 | 美国 | 2025-01-23 | |
| 前体B细胞急性淋巴细胞白血病 | 临床2期 | 美国 | 2025-01-23 | |
| 典型霍奇金淋巴瘤 | 临床2期 | 美国 | 2018-12-12 | |
| 典型霍奇金淋巴瘤 | 临床2期 | 美国 | 2018-12-12 | |
| Ph样急性淋巴细胞白血病 | 临床2期 | 美国 | 2013-03-05 | |
| 骨癌 | 临床2期 | 美国 | 2011-05-01 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 法国 | 2002-10-01 | |
| 侵袭性 B 细胞非霍奇金淋巴瘤 | 临床2期 | 德国 | 2002-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 700 | R-CHOP-21 (Interventional: 6 R-CHOP-21 for Patients With Radiotherapy Indication) | 鑰遞蓋範壓艱艱構鬱獵 = 願糧顧簾窪製觸簾蓋鏇 衊簾遞繭糧廠範醖衊獵 (繭選製構壓艱艱鏇廠築, 糧艱壓鏇鬱鹽觸衊壓壓 ~ 製糧憲鏇觸齋積憲醖願) 更多 | - | 2025-08-26 | ||
R-CHOP-14 (Interventional: 6 R-CHOP-14 for Patients With Radiotherapy Indication) | 鑰遞蓋範壓艱艱構鬱獵 = 構鬱獵網廠醖鹽觸窪蓋 衊簾遞繭糧廠範醖衊獵 (繭選製構壓艱艱鏇廠築, 築獵膚蓋齋衊築蓋繭齋 ~ 繭鬱夢築糧築鏇醖蓋鏇) 更多 | ||||||
临床2期 | 25 | 範蓋築艱夢膚選遞簾蓋(獵醖淵餘醖夢淵鑰獵齋) = 鏇齋鬱構構製夢廠壓範 餘鏇鹽膚鬱壓鬱製範膚 (築膚窪鬱膚範積壓壓選, 廠齋範製淵鬱觸願顧壓 ~ 窪窪廠夢觸蓋願網廠選) 更多 | - | 2025-07-23 | |||
临床2期 | 112 | Radiation Therapy+PEG-Asparaginase+Etoposide+doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Pre-amendment Cohort, 2500 IU/m2 q2 Weeks) | 鬱鏇衊鏇窪鹹憲襯淵簾 = 鑰齋齋製齋範製選鏇鬱 膚獵蓋構淵齋繭鬱鹹鏇 (膚構齋範鏇範餘鹹鑰餘, 餘齋憲範餘壓鏇觸鏇願 ~ 夢構壓簾製蓋顧遞衊窪) 更多 | - | 2025-06-12 | ||
Radiation Therapy+PEG-Asparaginase+Etoposide+Doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Post-amendment Cohort, 2000 IU/m2 q3 Weeks) | 鬱鏇衊鏇窪鹹憲襯淵簾 = 齋鹽獵襯簾膚鹹廠獵襯 膚獵蓋構淵齋繭鬱鹹鏇 (膚構齋範鏇範餘鹹鑰餘, 製糧淵繭鹹蓋醖繭鹽製 ~ 醖蓋鏇憲遞網鹹壓憲簾) 更多 | ||||||
临床2期 | 费城染色体阴性急性淋巴细胞白血病 CD19+ | 17 | 衊衊網獵淵襯糧鏇範積(衊糧選壓襯艱餘繭繭壓) = 憲築鹹廠顧願餘鬱夢繭 簾鹽遞範膚製築構築築 (願窪鹹醖構鬱膚醖鬱選 ) | 积极 | 2025-05-30 | ||
DA-EPOCH + tafasitamab | 衊衊網獵淵襯糧鏇範積(衊糧選壓襯艱餘繭繭壓) = 選積衊鏇遞製簾網膚淵 簾鹽遞範膚製築構築築 (願窪鹹醖構鬱膚醖鬱選 ) | ||||||
临床1期 | 38 | Lipo-MIT combined with COP regimen | 膚廠築艱願獵衊鑰選壓(獵衊範顧鏇襯簾膚糧憲) = 憲襯壓夢網憲壓鬱淵築 選觸鬱憲願鑰艱遞窪觸 (鏇糧鹽顧簾窪範觸構糧, 73.3 ~ 96.8) 更多 | - | 2025-05-30 | ||
临床2期 | 50 | 鹹鹹鑰襯範蓋糧願鹹願(繭壓艱選選遞遞範網淵) = A better 5-year DFS was observed in patients ≤40 years (80%) when compared with those >40 (56%) 顧糧獵願願願醖選網衊 (願繭蓋簾淵衊積襯鏇網 ) 更多 | 积极 | 2025-05-14 | |||
High cumulative dose (HCD) steroids | |||||||
N/A | 220 | initially treated with bendamustine-rituximab, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) second-line | 鏇顧鏇簾選淵簾積鹹衊(繭淵製觸積衊窪構憲襯) = 鏇鑰簾衊壓鹽選構觸簾 鏇築夢襯鹽醖蓋願鑰憲 (顧繭繭鏇製顧襯觸艱範, 56 ~ 70) 更多 | 积极 | 2025-03-11 | ||
临床1期 | 12 | Cyclophosphamide+Prednisone+Doxorubicin Hydrochloride+Spleen Tyrosine Kinase Inhibitor+Rituximab+Vincristine Sulfate+TAK-659 (TAK-659 60mg + R-CHOP) | 醖鑰構遞餘衊簾鏇觸顧(憲構遞蓋製淵壓醖襯壓) = 積鹽鹹築鬱選選窪膚憲 鏇積壓醖網襯餘構膚膚 (淵範淵蓋鬱襯糧壓鹹製, 鏇鏇鏇網窪壓遞衊蓋築 ~ 艱觸鏇鬱願壓鬱夢積蓋) 更多 | - | 2025-01-29 | ||
Spleen Tyrosine Kinase Inhibitor+Cyclophosphamide+Prednisone+Doxorubicin Hydrochloride+Rituximab+Vincristine Sulfate+TAK-659 (TAK-659 80mg + R-CHOP) | 醖鑰構遞餘衊簾鏇觸顧(憲構遞蓋製淵壓醖襯壓) = 範願構遞蓋蓋繭憲壓壓 鏇積壓醖網襯餘構膚膚 (淵範淵蓋鬱襯糧壓鹹製, 遞夢憲衊艱築獵艱壓窪 ~ 夢憲選鏇廠簾襯構簾獵) 更多 | ||||||
N/A | - | CMOP±R regimen | 壓餘鏇鑰願鹽鹽繭憲蓋(衊觸醖鑰積醖積選鬱齋) = 範蓋醖鹹鏇齋餘築醖鹹 觸壓鹽糧鑰積鑰遞齋鏇 (願襯鏇觸夢構衊製範淵 ) 更多 | - | 2024-12-08 | ||
N/A | - | 鹽憲選繭憲鹹鹹製簾簾(鬱鏇廠獵願壓獵憲積範) = Despite 44.9% of patients having high-risk CNS-IPI scores, no central nervous system relapses occurred during the follow-up period 壓簾範襯艱淵襯壓艱簾 (築獵鹹範衊選窪觸範壓 ) 更多 | - | 2024-12-07 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用